Denali Therapeutics (DNLI) Common Equity (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Common Equity data on file, last reported at $926.1 million in Q1 2026.

• On a quarterly basis, Common Equity fell 17.51% year-over-year to $926.1 million in Q1 2026; TTM through Mar 2026 was $926.1 million, a 17.51% decrease from a year earlier, with the FY2025 full-year figure at $1.0 billion, down 17.56% from the prior year.
• Common Equity for Q1 2026 stood at $926.1 million, down from $1.0 billion in the prior quarter.
• Over the last five years, Common Equity for DNLI reached as high as $1.5 billion in Q1 2024 and fell as low as $1.8 million in Q3 2025.
• Historically, Common Equity has averaged $1.0 billion across 5 years, with a median of $1.0 billion in 2023.
• Across the five-year window, Common Equity soared 50.56% in 2024 and plunged 99.86% in 2025, its largest moves.
• Year by year, Common Equity stood at $1.0 billion in 2022, then fell by 1.1% to $1.0 billion in 2023, then grew by 19.28% to $1.2 billion in 2024, then dropped by 17.56% to $1.0 billion in 2025, then slipped by 8.65% to $926.1 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $926.1 million in Q1 2026, $1.0 billion in Q4 2025, and $1.8 million in Q3 2025.